Company intelligence / Profile preview

MPC Investments

Geneva, Geneva Canton, Switzerlandcbinsights.com ↗

Ownership: Private
Development stage: Other

Overview

Preclinical studies show that adding MPC-targeting small molecules during CAR-T cell preparation improves survival and durability of these cells in cancer models compared to standard approaches. The company aims to enter clinical trials with its lead product as a supplement/adjuvant for cell therapies, and is expanding into other indications such as alopecia, kidney fibrosis, and neurodegeneration.

Therapeutic areas: NeurologyOncologyDermatologyNephrology
Modalities: Small moleculeCell therapy supplement (media additive)
Industry: Biotech

Beyond the preview

Go deeper on MPC Investments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPC Investments.

Explore the full profile